Intra-Cellular Therapies Inc (NASDAQ:ITCI)

42.61
Delayed Data
As of 4:00pm ET
 +3.71 / +9.54%
Today’s Change
28.40
Today|||52-Week Range
55.20
-18.59%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$4.0B

Company Description

Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company. It focuses on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. The firm's lead product candidate, ITI-007, is in clinical development as a first-in-class treatment for schizophrenia. It also includes pre-clinical programs that are focused on advancing drug candidates for the treatment of cognitive dysfunction, in both schizophrenia and Alzheimer's disease and for disease modification and the treatment of neurodegenerative disorders, including Alzheimer's disease. The company was founded by Paul Greengard and Sharon Mates on August 29, 2013 and is headquartered in New York, NY.

Contact Information

Intra-Cellular Therapies, Inc.
430 East 29th Street
New York New York 10016
P:(464) 440-9333
Investor Relations:
1646

Employees

Shareholders

Mutual fund holders52.46%
Other institutional32.43%
Individual stakeholders15.40%

Top Executives

Sharon MatesChairman, President & Chief Executive Officer
Lawrence J. HinelineChief Financial Officer, Treasurer & SVP-Finance
Robert E. DavisChief Scientific Officer & Senior Vice President
Suresh DurgamChief Medical Officer & Senior Vice President
Karen Patruno SheehyChief Compliance Officer & Senior Vice President